Loading...
Market
Will dengue cases in India decrease in 2025 compared to 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
National Centre for Vector Borne Diseases Control Programme annual report
Story
ICMR and Panacea Biotec Start Phase 3 Trial for DengiAll, India's First Indigenous Dengue Vaccine
Aug 14, 2024, 12:15 PM
The Indian Council of Medical Research (ICMR) and pharmaceutical company Panacea Biotec have initiated the first-ever Phase 3 clinical trial for a dengue vaccine in India. The indigenous vaccine, named DengiAll, marks a significant advancement in the fight against dengue. The trial began with the administration of the first dose in Rohtak, Haryana, ahead of India's Independence Day 2024. This development comes as dengue cases remain a concern in India, with 289,235 cases and 485 deaths reported in 2023, according to the National Centre for Vector Borne Diseases Control Programme.
View original story
Similar markets
Less than 30,000 • 25%
30,000 to 40,000 • 25%
40,001 to 50,000 • 25%
More than 50,000 • 25%
Below 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
Above 3 million • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,001 to 15,000 • 25%
More than 15,000 • 25%
Brazil • 25%
India • 25%
Indonesia • 25%
Philippines • 25%
Less than 50% • 25%
50% to 99% • 25%
100% to 149% • 25%
150% or more • 25%
Florida • 25%
Texas • 25%
California • 25%
Other • 25%